Table 2.

IFN-γ, TNF-α, IL-1β, IL-5, IL-13 and MIF from subjects’s PBMCs

Zn (μM)	IFN-γ (pg/mL)	TNF-α (pg/mL)	IL-1β (pg/mL)	IL-5 (pg/mL)	IL-13 (pg/mL)	MIF (ng/mL)
Patient 1
0	1.7	1.4	1.3	0.3	<0.2	1.5
5	5.2	38.2	1.6	0.5	1.3	1.5
50	11.6	42.8	18.9	2.6	7.9	2.8
10	19.3	71.3	22.5	5.8	18.7	7.8
Patient 2
0	1.3	<0.01	0.8	<0.2	<0.2	2.1
5	10.5	30.2	1.0	<0.2	3.6	3.2
50	17.2	50.5	20.3	3.7	10.6	5.4
100	25.3	88.8	24.2	6.9	16.3	8.0
Patient 3
0	0.9	0.3	1.2	<0.2	0.3	5.3
50	9.8	15.2	1.7	0.3	5.5	6.8
50	12.3	13.8	20.1	3.8	14.6	6.2
100	20.5	19.1	26.6	9.2	2.3	6.9
Patient 4
0	1.6	<0.01	0.9	<0.2	0.4	0.8
5	8.3	12.1	0.8	0.8	9.6	1.2
50	15.5	13.2	12.3	2.1	14.5	3.8
100	20.3	15.7	18.9	6.3	20.3	9.7
Patient 5
0	0.7	0.4	<0.04	<0.2	<0.2	1.3
5	1.0	5.5	0.8	1.0	<0.2	2.4
50	5.6	11.2	18.6	11.5	13.2	3.2
100	13.3	35.0	23.5	20.7	19.7	7.0
Control 1
0	1.2	<0.01	0.5	<0.2	0.9	1.1
5	1.6	<0.01	0.9	0.3	1.0	1.3
50	6.3	<0.01	1.5	0.5	1.3	3.8
100	8.5	<0.01	2.3	0.5	1.5	2.6
Control 2
0	1.7	<0.01	1.1	<0.2	0.5	0.4
5	3.6	<0.01	1.5	0.4	0.8	0.3
50	4.9	<0.01	1.8	0.4	0.8	0.8
100	6.3	<0.01	1.8	0.8	1.2	0.6
Control 3
0	1.8	<0.01	0.8	<0.2	0.6	0.2
5	3.2	<0.01	1.1	<0.2	0.6	1.1
50	5.1	<0.01	1.3	<0.2	1.0	0.4
100	7.2	<0.01	1.6	0.4	1.1	1.1
Control 4
0	0.9	<0.01	1.0	0.1	0.8	1.4
5	2.6	<0.01	0.9	0.1	0.9	1.3
50	4.9	<0.01	1.1	0.1	0.9	1.0
100	7.8	<0.01	1.8	0.4	1.2	0.9
Control 5
0	0.3	<0.01	<0.04	<0.2	<0.2	0.3
5	0.3	<0.01	<0.04	0.3	<0.2	0.5
50	0.7	<0.01	<0.04	1.0	<0.2	0.6
100	1.6	<0.01	0.4	0.3	<0.2	0.3